Versartis (VSAR) Tops Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Versartis (VSAR) Tops Q4 EPS by 2c

Versartis Reports Fourth Quarter and Full Year 2015 Financial Results

February 18, 2016 4:05 PM EST

MENLO PARK, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ: VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the fourth quarter and full year ended December 31, 2015.

Over the past year, we have made tremendous progress advancing the development of somavaratan in the US and globally having initiated three late stage clinical trials, commented Jay Shepard, Chief Executive Officer. VELOCITY, our Phase 3 trial for pediatric patients, and VITAL, our Phase 2... More